QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

$41.17
-0.34 (-0.82%)
(As of 04:32 PM ET)
Today's Range
$41.01
$42.05
50-Day Range
$41.40
$47.13
52-Week Range
$13.81
$47.74
Volume
404,820 shs
Average Volume
862,641 shs
Market Capitalization
$3.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.55

IDEAYA Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
8.2% Upside
$44.55 Price Target
Short Interest
Bearish
14.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.48mentions of IDEAYA Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$3.77 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.26) to ($2.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Medical Sector

489th out of 930 stocks

Pharmaceutical Preparations Industry

225th out of 422 stocks

IDYA stock logo

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Stock Price History

IDYA Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Ideaya inks clinical trial pact with Merck
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts
Recap: IDEAYA Biosciences Q4 Earnings
IDEAYA Biosciences Q4 Results Misses Estimates
Ideaya Biosciences: A Strong Bet In Targeted Oncology
IDYA Apr 2024 35.000 put
IDYA Apr 2024 45.000 put
IDYA Mar 2024 35.000 put
See More Headlines
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/16/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IDYA
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.55
High Stock Price Target
$60.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+6.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

Net Income
$-112,960,000.00
Net Margins
-483.05%
Pretax Margin
-483.05%

Debt

Sales & Book Value

Annual Sales
$23.39 million
Book Value
$9.64 per share

Miscellaneous

Free Float
70,832,000
Market Cap
$3.11 billion
Optionable
Optionable
Beta
0.80
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Yujiro S. HataMr. Yujiro S. Hata (Age 50)
    President, CEO & Director
    Comp: $851.7k
  • Dr. Michael A. White Ph.D. (Age 58)
    Chief Scientific Officer
    Comp: $613.85k
  • Dr. Darrin M. Beaupre M.D. (Age 57)
    Ph.D., Chief Medical Officer
    Comp: $152.64k
  • Mr. Andres Ruiz Briseno CPA (Age 37)
    Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations
  • Dr. Paul A. Barsanti Ph.D.
    Chief Technology Officer
  • Mr. Jason S. Throne Esq. (Age 52)
    J.D., Chief Legal Officer & Company Secretary
    Comp: $425.56k
  • Mr. Mick O'Quigley
    Chief of Staff & Clinical Development

IDYA Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings
or view top-rated stocks.

What is IDEAYA Biosciences' stock price target for 2024?

13 brokerages have issued 12 month price objectives for IDEAYA Biosciences' stock. Their IDYA share price targets range from $24.00 to $60.00. On average, they expect the company's share price to reach $44.55 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price.
View analysts price targets for IDYA
or view top-rated stocks among Wall Street analysts.

How have IDYA shares performed in 2024?

IDEAYA Biosciences' stock was trading at $35.58 at the beginning of 2024. Since then, IDYA stock has increased by 15.7% and is now trading at $41.17.
View the best growth stocks for 2024 here
.

Are investors shorting IDEAYA Biosciences?

IDEAYA Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average daily trading volume, of 905,000 shares, the days-to-cover ratio is presently 10.4 days. Currently, 14.3% of the shares of the company are short sold.
View IDEAYA Biosciences' Short Interest
.

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IDYA earnings forecast
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its earnings results on Tuesday, February, 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. The firm earned $3.90 million during the quarter, compared to the consensus estimate of $8.84 million. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 23.00% and a negative net margin of 483.05%. IDEAYA Biosciences's revenue for the quarter was down 3.0% on a year-over-year basis.

What ETFs hold IDEAYA Biosciences' stock?
What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDYA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners